e-learning
resources
Virtual 2020
Pre-Congress Content
Asthma and cough: clinical trials and pharmacological insights
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Tiotropium improved asthma symptoms and increased time to first exacerbation in patients with moderate-to-severe asthma.
B. Omarjee (Saint-Denis (La Réunion), Reunion)
Source:
Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights
Session:
Asthma and cough: clinical trials and pharmacological insights
Session type:
E-poster session
Number:
2274
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
B. Omarjee (Saint-Denis (La Réunion), Reunion). Tiotropium improved asthma symptoms and increased time to first exacerbation in patients with moderate-to-severe asthma.. 2274
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV
1
in patients with severe persistent allergic asthma irrespective of age
Source: Eur Respir J 2005; 26: Suppl. 49, 48s
Year: 2005
Tiotropium add-on therapy reduces seasonal peaks of asthma worsening in adults with symptomatic severe asthma
Source: Eur Respir J, 55 (1) 1900964; 10.1183/13993003.00964-2019
Year: 2020
Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma
Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues
Year: 2017
Budesonide/formoterol for maintenance and relief in adolescents with asthma: fewer exacerbations and improved asthma control
Source: Eur Respir J 2004; 24: Suppl. 48, 164s
Year: 2004
Omalizumab reduces asthma exacerbations in children (6–<12 years) with moderate-to-severe allergic (IgE-mediated) asthma irrespective of baseline LABA use
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009
Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline
Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges
Year: 2009
Omalizumab (Xolair®) reduces exacerbations in patients with moderate-to-severe persistent allergic asthma independent of former smoking status
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008
Tiotropium reduces asthma exacerbations in asthmatic patients with persistent airflow obstruction uncontrolled despite treatment in accordance with guidelines
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012
The association between airway and systemic eosinophilia and symptoms and exacerbations differ between asthma and COPD patients
Source: Virtual Congress 2020 – Monitoring of inflammation in remodelling
Year: 2020
Ceruloplasmine efficacy in patients with asthma exacerbations
Source: Annual Congress 2011 - Novel mechanisms in lung injury
Year: 2011
Effect of dupilumab on severe exacerbations in asthma patients with and without lung function improvements
Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Year: 2020
Mild improvement in symptoms and pulmonary function in a long-term follow-up of patients with TDI-induced asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 604s
Year: 2005
QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis
Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside
Year: 2017
Once-daily glycopyrronium improves lung function and reduces exacerbations in severe-to-very severe COPD patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
Impact of omalizumab in patients with severe asthma
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009
COPD patients with asthma, characteristics and risk of exacerbations
Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD
Year: 2019
Predictors of severe asthma exacerbations, poor asthma control and beta-agonist overuse in adult asthma
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013
Salmeterol 50μg bid significantly reduces moderate-severe exacerbations in patients with all severities of COPD
Source: Eur Respir J 2003; 22: Suppl. 45, 68s
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept